May 28, 2013
Astellas Pharma announced on May 24 that it has filed a new drug application (NDA) in Japan for the investigational oral androgen receptor signaling inhibitor enzalutamide (development code: MDV3100; brand name in the US: Xtandi), which is being codeveloped by...read more